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Re-evaluation of the Diagnostic Criteria for Wilson
Disease in Children With Mild Liver Disease
Emanuele Nicastro*, Giusy Ranucci*, Pietro Vajro, Angela Vegnente, and Raffaele Iorio
The diagnosis of Wilson disease (WD) is challenging, especially in children. Early detec-
tion is desirable in order to avoid dramatic disease progression. The aim of our study was
to re-evaluate in WD children with mild liver disease the conventional diagnostic criteria
and the WD scoring system proposed by an international consensus in 2001. Forty chil-
dren with WD (26 boys and 14 girls, age range 5 1.1-20.9 years) and 58 age-matched and
sex-matched patients with a liver disease other than WD were evaluated. Both groups were
symptom-free and had elevated aminotransferases as predominant signs of liver disease. In
all WD patients, the diagnosis was supported by molecular analysis, the liver copper con-
tent, or both. A receiver operating characteristic (ROC) analysis of ceruloplasmin at the
cutoff value of 20 mg/dL showed a sensitivity of 95% [95% conﬁdence interval (CI) 5
83%-99.4%] and a speciﬁcity of 84.5% (95% CI 5 72.6%-92.6%). The optimal basal uri-
nary copper diagnostic cutoff value was found to be 40 lg/24 hours (sensitivity 5 78.9%,
95% CI 5 62.7%-90.4%; speciﬁcity 5 87.9%, 95% CI 5 76.7%-95%). Urinary copper
values after penicillamine challenge did not signiﬁcantly differ between WD patients and
control subjects, and the ROC analysis showed a sensitivity of only 12%. The WD scoring
system was proved to have positive and negative predictive values of 93% and 91.6%,
respectively. Conclusion: Urinary copper excretion greater than 40 lg/24 hours is sugges-
tive of WD in asymptomatic children, whereas the penicillamine challenge test does not
have a diagnostic role in this subset of patients. The WD scoring system provides good
diagnostic accuracy. (HEPATOLOGY 2010;000:000-000.)
W
ilson disease (WD) is an autosomal reces-
sive disorder of copper metabolism caused
by mutations in a gene [ATPase, Cuþþ
transporting, beta polypeptide (ATP7B)] encoding a
copper-transporting, P-type ATPase.1 This disease leads
to progressive copper accumulation in the liver and
subsequent deposition in other organs, such as the
nervous system, corneas, kidneys, bones, and joints.
The distribution of the metal in diverse organs over
time accounts for the wide range of clinical manifesta-
tions.2 In the pediatric age bracket, most cases have a
hepatic presentation. In the available series, the per-
centage of WD children presenting with isolated ele-
vated serum aminotransferases ranges from 14% to
88%; this depends on the health policy and the type
of health care provided.3-5 However, there is evidence
that alterations in liver function tests may precede the
onset of symptoms for a considerable time. Neurologi-
cal symptoms are more frequent in adolescents and
young adults6-8 and are found in only 4% to 6% of
pediatric cases with hepatic onset.4,5,9
If WD is not recognized and adequately treated, the
progression of hepatic and neurological damage can be
very rapid, and fulminant liver failure can occur.
Therefore, the prompt detection of this condition is
vital. Unfortunately, the diagnosis of WD is an espe-
cially challenging task in children because the conven-
tional criteria established for adults are not always
appropriate for children.10 In particular, basal urinary
copper excretion in most WD children is lower than
the extensively accepted cutoff value of 100 lg/24
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hours.10 Additionally, the diagnostic accuracy of daily
urinary copper measurements after chelation with pen-
icillamine remains questionable.
From a genetic point of view, the diagnosis of WD
is based on the identiﬁcation of two disease-causing
mutations or homozygosity for a single disease-causing
mutation. However, according to the American Associ-
ation for the Study of Liver Diseases (AASLD) guide-
lines, mutation analysis should be performed for indi-
viduals in whom the diagnosis is difﬁcult to establish
by clinical and biochemical testing.2
In order to obtain a more reliable diagnosis of WD,
a scoring system was proposed by an international con-
sensus of experts.11 To date, this score has not been
extensively evaluated in asymptomatic WD children.
The aim of our study was to re-evaluate in WD
children with mild liver disease the conventional diag-
nostic criteria and the WD scoring system proposed
by Ferenci et al.11
Patients and Methods
Patients We collected data for all patients with WD
who were referred to the Department of Pediatrics
(University Federico II, Naples, Italy) between 1984
and 2009 for the diagnostic investigation of elevated
serum aminotransferases or for familial screening for
WD. The diagnosis of WD was initially established
with at least two of the following features: a low
plasma ceruloplasmin level (<20 mg/dL), an increased
basal urinary copper level (>100 lg/24 hours), an
increased urinary copper level after the penicillamine
challenge test (PCT; >1575 lg/24 hours), an
increased liver copper level (>250 lg/g of dry weight),
a positive family history, the presence of Kayser-
Fleischer (KF) rings, and Coombs’ negative hemolytic
anemia.3 Furthermore, genetic testing results, when
available, were considered.
In order to re-evaluate the accuracy of the diagnostic
criteria for WD in children with mild liver disease, we
decided to analyze only patients for whom the diagno-
sis of WD was supported by the presence of an abnor-
mal liver copper value, the identiﬁcation of two dis-
ease-causing mutations or homozygosity for a single
disease-causing mutation, or both. Therefore, of the
43 patients (28 males and 15 females) who fulﬁlled
the aforementioned diagnostic criteria, 40 (26 males
and 14 females, median age at diagnosis ¼ 6.1 years,
range ¼ 1.1-20.9) were selected for the study.
We recruited for the control group patients with a
liver disease other than WD who were being investi-
gated for elevated serum aminotransferases and siblings
of WD patients who were referred to our center in the
same period to exclude a diagnosis of WD. Patients
were included in the control group if, on at least one
occasion, the levels of ceruloplasmin, basal urinary
copper, and urinary copper after penicillamine chal-
lenge were tested.
Patients were considered to be affected by cryptogenic
liver disease when the following entities were ruled out:
WD, alpha-1-antitrypsin deﬁciency, infectious hepatitis,
autoimmune hepatitis (AIH), biliary system disorders,
drug-induced liver disease, nonalcoholic fatty liver dis-
ease (NAFLD), celiac disease, cystic ﬁbrosis, congenital
disorders of glycosylation (CDG), and extrahepatic
causes of elevated serum aminotransferases.
The following data at diagnosis were analyzed: age,
sex, reason for referral, clinical symptoms, laboratory
tests (e.g., levels of serum ceruloplasmin, basal urinary
copper, urinary copper after PCT, and hepatic copper),
and molecular analysis for ATP7B. The WD diagnos-
tic scores were calculated in accordance with Ferenci
et al.11 and are shown in Table 1. The diagnosis of
WD was considered certain if the ﬁnal score was 4 or
more and probable if it was 2 to 3. Assigning points
for urinary copper, we considered as upper limits of
normal (ULNs) both 100 and 40 lg/24 hours. We
initially calculated the score without taking into
account the mutation analysis.
Among the enrolled WD patients, 34 were referred
for raised serum aminotransferases, and 6 were referred
for familial screening. Twenty-three subjects (57.5%)
presented with hepatomegaly at the clinical examina-
tion, ultrasound examination, or both. In ﬁve patients
(12.5%), neurological signs were highlighted after a
detailed neurological examination when the WD diag-
nosis was already known, and in two of these ﬁve
patients, KF rings were detected. Molecular analysis
for the ATP7B gene was performed for 36 patients,
and disease-causing mutations were found in 34 (26
homozygotes and 8 heterozygotes). The characteristics
of the WD patients are shown in Table 2.
Fifty-eight patients (36 males and 22 females, me-
dian age at diagnosis ¼ 7.1 years, range ¼ 1-20) were
enrolled as control subjects. Among them, 52 patients
who were referred for elevated serum aminotransferases
had a liver disease other than WD: 17 (29.3%) had
NAFLD, 13 (22.4%) had chronic cryptogenic liver
disease, 5 (8.6%) had AIH, 5 had nodular regenerative
hyperplasia (NRH) of the liver, 4 (6.8%) had CDG, 2
(3.44%) had congenital hepatic ﬁbrosis, and 2
(3.44%) had Klippel-Tre´naunay-Weber syndrome with
hepatic vascular malformations. Furthermore, celiac
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disease, chronic hepatitis C, Alagille syndrome, and
sclerosing cholangitis were each present in a single
case. The remaining six patients were recruited after
familial screening and did not carry any mutation
according to the molecular analysis of ATP7B.
Methods Liver function tests and other routine lab-
oratory data were obtained with standard methods.
The ceruloplasmin concentration in serum was meas-
ured by radial immunodiffusion (NOR-Partigen
Coeruloplasmin, Behring, Marburg, Germany; normal
range ¼ 20-60 mg/dL).12 Urine samples (basal urinary
copper and urinary copper after PCT) were collected
in an acid-washed, plastic, metal-free container. PCT
urinary copper was evaluated after patients ingested
500 mg of D-penicillamine at time zero and again at
12 hours while 24-hour urinary copper collection pro-
gressed.13 Copper levels in urine were determined by
ﬂame atomic absorption spectrophotometry as previ-
ously described.14 Liver biopsy was performed by the
Menghini technique with a disposable biopsy set
(Hepaﬁx, Braun, Melsungen, Germany). Copper levels
in dried liver tissue were determined by ﬂame atomic
absorption spectroscopy according to Kingston and
Jassie15 (normal range ¼ 6-50 lg/g of dry weight). All
slides were examined by the same pathologist, and
lesions were evaluated according to the recommenda-
tions of Batts and Ludwig.16
For the molecular analysis of the ATP7B gene,
DNA extraction and polymerase chain reaction were
carried out with the standard methods by Dr. Georgios
Loudianos (Ospedale Regionale per le Microcitemie,
Cagliari, Italy). With single-strand conformational
polymorphism and sequencing methods, patients were
analyzed for the 12 exons (5, 6, 8, 10, and 12-19) on
which most mutations reside according to previous
studies of the Italian continental population. DNA
samples not completely characterized by the ﬁrst step
of analysis or those found to have a new missense
mutation were further analyzed for the remaining
exons of the ATP7B gene by single-strand conforma-
tional polymorphism and sequencing analysis.17
Statistical Analysis Continuous variables (cerulo-
plasmin, urinary copper, and liver copper) were pre-
sented as numbers of patients, means, medians, and
standard deviations, whereas discrete variables (clinical
manifestations at presentation and the presence or ab-
sence of KF rings) were presented as percentages. Nor-
mally distributed continuous variables were presented
as means and standard deviations and were compared
between groups by analysis of variance with post hoc
testing (Scheffe’s test). Continuous variables that were
not normally distributed in the analyzed population
were presented as medians and ranges and were com-
pared between groups by Kruskal-Wallis analysis of
variance with post hoc testing (Mann-Whitney U test).
Receiver operating characteristic (ROC) analysis
was performed to determine the sensitivity and speci-
ﬁcity with 95% conﬁdence intervals (CIs) for the fol-
lowing variables at different previously proposed cut-
off values: ceruloplasmin (cutoffs of 20, 14, and 10
mg/dL were considered),18 basal 24-hour urinary
copper [cutoffs of 100 (1.6 lmol/24 hours) and 40
lg/24 hours (0.6 lmol/24 hours) were considered],2
and 24-hour urinary copper after PCT [cutoffs of
Table 1. Diagnostic Scoring System for WD
Biochemistry Score Clinical Symptoms and Signs Score
Liver copper content (in the absence of cholestasis) KF rings
Normal (<50 lg/g of dry weight) 1 Absent 0
<5 times ULN (50-250 lg/g of dry weight) þ1 Present þ1
>5 times ULN (>250 lg/g of dry weight) þ2 Coombs’ negative hemolytic anemia
Rhodanine stain* Absent 0
Absent 0 Present þ1
Present þ1 Neuropsychiatric symptoms suggestive of WD
Serum ceruloplasmin and/or typical brain magnetic resonance imaging
Normal (>20 mg/dL) 0 Absent 0
10-20 mg/dL þ1 Mild þ1
<10 mg/dL þ2 Severe þ2
Daily urinary copper excretion ATP7B genetic analysis
Normal 0 No mutation found 0
1-2 times ULN þ1 Mutation on one chromosome þ1
>2 times ULN þ2 Mutations on both chromosomes þ4
Normal but >5 times ULN after PCT þ2
This table was adapted from Ferenci et al.11 A score  4 indicates that disease is highly likely, a score of 2 or 3 indicates that disease is probable and further
investigations are needed, and a score of 0 or 1 indicates that disease is unlikely.
*When the quantitative liver copper content was not available.
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1575 (25 lmol/24 hours), 500 (8 lmol/24 hours),
and 200 lg/24 hours (3.2 lmol/24 hours) were
considered].9,11
Linear regression analysis was applied to assess the
dependence of urinary copper excretion and liver cop-
per contents on age, and the Pearson correlation coefﬁ-
cient (r) was deﬁned.
All P values were based on two-tailed comparisons,
and those less than 0.05 were considered to indicate
statistical signiﬁcance.
All statistical analysis was performed with GraphPad
Prism 5.00 for Mac (GraphPad Software, San Diego, CA).
Results
In Figure 1, WD patients and control subjects are
plot-scattered with respect to the results for each diag-
nostic test for WD. In Fig. 2, ROC curves for cerulo-
plasmin, basal 24-hour urinary copper, and 24-hour
urinary copper after PCT are shown.
Table 2. Characteristics of 40 Children With WD
Patient Sex
Age at
Diagnosis
(Months)
KF
Rings
Serum
Copper
(lg/dL)
Ceruloplasmin
(mg/dL)
Basal
Urinary
Copper
(lg/24
Hours)
Urinary
Copper
After PCT
(lg/24
Hours)
Hepatic
Copper
(lg/g of
Dry Weight)
Liver
Biopsy
ATP7B
Genotype
WD
Score*
WD
Scorey
1 Male 65 Neg ND 16 270 ND 1129 S, F p.H1069Q/p.H1069Q 5 5
2 Male 60 Neg <40 3 139 517 532 S, F p.T7858A/c.51þ4A>T 6 5
3 Male 174 Neg 53 20 130 1452 390 S, C, ACH c.2122-8T>G/p.T1288M 5 4
4 Male 73 Neg <40 8 262 ND 1056 S, F c.2447þ5G>A/c.2447þ5G>A 6 6
5 Male 58 Neg <40 6 241 332 1048 S c.2447þ5G>A/c.2447þ5G>A 6 6
6 Male 52 Neg ND 2 40 302 1203 S, F p.R1319X/unknown 5 4
7 Male 251 Pos ND 2 413 1469 60 S, F p.T1220M/unknown 7 7
8 Female 79 Neg <40 2 119 ND 1041 S, F p.T1220M/c.51þ4A>T 6 5
9 Female 29 Neg 6 2 22 ND 1002 S, F p.T1220M/c.51þ4A>T 4 4
10 Female 16 Neg <40 3 15 ND ND ND p.P840L/p.N1270S NA NA
11 Male 87 Neg <40 2 135 ND 919 S, F, ACH p.P840L/p.N1270S 6 5
12 Female 92 Neg 64 18 108 872 714 S, F p.H1069Q/p.R1041P 5 4
13 Male 74 Neg <20 2 116 ND 260 S, F p.R1319X/p.R1319X 6 5
14 Male 100 Neg <10 2 236 ND ND S, F p.S1369L/p.S1369L NA NA
15 Male 125 Neg 64 18.8 300 ND 300 F p.H1069Q/H 1207 Pro 5 5
16 Male 72 Neg 50 12 228 ND <50 S, F p.H1069Q/p.T1220M 3 3
17 Male 36 Neg ND 16 31 ND ND ND p.H1069Q/p.T1220M NA NA
18 Female 80 Neg 25 2 117 969 ND ND p.P840L/p.N1270S NA NA
19 Female 78 Neg 71 15 180 378 514 S, F p.H1069Q/unknown 5 4
20 Male 108 Neg 79 23 198 ND 750 S, F p.H1069Q/p.H1069Q 4 3
21 Male 19 Neg <40 6 15 580 ND ND c.2299insG/c.2299insG NA NA
22 Female 13 Neg 3 7 ND ND ND ND c.2299insG/c.2299insG NA NA
23 Female 48 Neg <40 8 4 150 1060 F No mutation found 4 4
24 Male 96 Neg <40 5 14 402 250 F No mutation found 5 3
25 Male 25 Neg ND 10 ND ND ND ND p.H1069Q/p.H1069Q NA NA
26 Male 101 Neg 80 19 120 859 ND ND p.H1069Q/p.H1069Q NA NA
27 Female 70 Neg <40 7 172 ND 676 S, F ND 6 5
28 Female 84 Neg 11 3 145 1829 600 F ND 6 5
29 Female 108 Neg <40 4 91 281 1215 F ND 6 4
30 Male 84 Neg 19 5 234 526 250 S c.2447þ5G>A/unknown 5 5
31 Female 72 Neg 19 20 78 630 1700 S, ACH, C ND 4 5
32 Male 39 Neg 71 3 25 64 904 S, F c.2304dupC/unknown 4 4
33 Male 56 Neg <40 2 138 802 1660 S, F c.2304dupC/unknown 6 5
34 Female 63 Neg ND 38 66 944 785 S, F c.3895delC/unknown 3 4
35 Male 72 Neg <40 19 41 888 ND ND p.Y594X/p.G1061E NA NA
36 Male 251 Neg ND 19 223 143 ND ND p.Y594X/p.G1061E NA NA
37 Male 192 Pos <40 6 165 1646 970 S, F p.H1069Q/p.N1270S 8 7
38 Male 90 Neg ND 3 141 1600 1350 C c.2532delA/unknown 6 5
39 Female 72 Neg ND 8 157 397 1449 S p.I899F/p.N1270S 6 5
40 Male 73 Neg ND 18 150 1251 620 ND p.H1069Q/p.G711E 5 4
The WD scores were calculated under the assumption of urinary copper ULNs of
*40 and
†100 lg/24 hours.
Abbreviations: ACH, active chronic hepatitis; C, cirrhosis; F, ﬁbrosis; NA, not applicable; ND, not done; Neg, negative; Pos, positive; S, steatosis.
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The serum ceruloplasmin concentration was signiﬁ-
cantly lower in children with WD (9.6 6 1.3 mg/dL)
versus controls (27.45 6 0.9 mg/dL, P < 0.0001).
Notably, only 2 of 40 WD patients (5%) had serum
ceruloplasmin levels > 20 mg/dL, whereas 13 (32.5%)
had values between 10 and 20 mg/dL. Among control
subjects, 10 of 58 (17.24%) had ceruloplasmin levels
 20 mg/dL: 4 had CDG, 3 had NAFLD, 2 were
picked up by familial screening and did not carry any
mutation, and 1 had congenital hepatic ﬁbrosis. It is
remarkable that all children with CDG had hypoceru-
loplasminemia. We performed an ROC analysis of cer-
uloplasmin for 40 WD patients and all 58 control
subjects. The analysis suggested that the most useful
cutoff value was 20 mg/dL, which had a sensitivity of
95% (95% CI ¼ 83%-99.4%) and a speciﬁcity of
84.5% (95% CI ¼ 72.6%-92.6%).
Basal 24-hour urinary copper excretion was signiﬁ-
cantly higher in patients with WD (138.9 6 15.1 lg/
24 hours) versus controls (20.9 6 2.9 lg/24 hours,
P < 0.0001). Among WD patients, 12 of 38 (31.5%)
and 7 of 38 (18.4%) had basal urinary copper levels <
100 lg/24 hours and < 40 lg/24 hours, respectively.
Among seven children with urinary copper levels < 40
lg/24 hours (four males and three females, median age
¼ 3 years, range ¼ 1.3-8), ﬁve were picked up with
familial screening. In the control group, 4 of 58
patients (6.8%) had urinary copper levels  40 lg/24
hours: 2 had NAFLD, 1 had NRH, 1 had AIH type 2,
and all had urinary copper levels < 100 lg/24 hours.
An ROC analysis of 38 WD patients and 58 controls
conﬁrmed that a threshold of 40 lg/24 hours (sensitiv-
ity ¼ 78.9%, 95% CI ¼ 62.7%-90.4%) provided ac-
ceptable diagnostic accuracy in identifying WD with
respect to 100 lg/24 hours for basal urinary copper
(sensitivity ¼ 65.8%, 95% CI ¼ 48.6%-80.4%).
Moreover, basal urinary copper was directly correlated
with the age at diagnosis (r ¼ 0.58, P < 0.0001) in
children with WD but not in the control group.
The daily urinary copper level after PCT did not
statistically differ between patients with WD (771.3 6
103.3 lg/24 hours) and controls (585.5 6 63.8 lg/24
hours, P ¼ 0.69). Among WD patients, only 3 of 25
(12%) presented values > 1575 lg/24 hours: all of
them had ﬁbrosis at liver biopsy and basal copper
excretion > 100 lg/24 hours. Among controls, 3 of
58 (5.2%) had PCT cupriuria > 1575 lg/24 hours,
and they presented with NASH, NRH, or AIH type
Fig. 1. Results of diagnostic tests for patients with WD and control subjects: (A) ceruloplasmin, (B) basal 24-hour urinary copper, (C) 24-hour
urinary copper after PCT, and (D) liver copper. *P < 0.0001. The broken lines represent the best cutoff for each test. NS, not signiﬁcant.
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1. The ROC analysis (area under the curve ¼ 0.61, P ¼
0.10) of 25 WD patients and 58 controls showed that at
the cutoff value of 1575 lg/24 hours, the sensitivity was
only 12% (95% CI ¼ 2.5%-31.2%); it was raised to
64% (95% CI ¼ 42.5%-82%) and 88% (95% CI ¼
68.8%-97.4%) only when the threshold was lowered to
>500 lg/24 hours and >200 lg/24 hours, respectively.
Liver copper levels were measured in 30 WD patients
and 24 control subjects and signiﬁcantly differed between
the two groups (813.6 6 81.7 versus 38.4 6 17 lg/g of
dry weight, P < 0.0001). Only 2 of 30 WD patients
(7%) had a liver copper level < 75 lg/g of dry weight,
which has been proposed as a novel diagnostic threshold19;
the remaining 28 had values > 250 lg/g of dry weight.
Liver copper levels in WD patients did not directly corre-
late with the severity of the histological picture (data not
shown) or the age at liver biopsy (r ¼ 0.38, P ¼ 0.03).
Among controls, 4 of 24 (6%) had liver copper levels >
50 lg/g of dry weight; 2 had CDG (318 and 250 lg/g
of dry weight, respectively), 1 had NRH, and 1 had
cryptogenic liver disease. The two patients affected by
CDG also had low ceruloplasmin levels.
The sensitivity and speciﬁcity of ceruloplasmin, ba-
sal 24-hour urinary copper, and 24-hour urinary cop-
per after PCT at different thresholds are summarized
in Table 3.
An evaluation of all items of the WD scoring system
proposed by Ferenci et al.11 was possible in 30 patients
with WD and in 24 control subjects. When the consid-
ered cutoff value for basal urinary copper was 40 lg/24
hours, only two patients with WD scored less than 4;
when the cutoff value was 100 lg/24 hours, three
patients did. Only two control subjects, both of whom
had CDG, had a score of 4 regardless of the consid-
ered cutoff value (Fig. 3). When we considered 40 lg/
24 hours instead of 100 lg/24 hours as the urinary
copper ULN, the scoring system had the best diagnos-
tic accuracy: a sensitivity of 93% versus 90%, a speci-
ﬁcity of 91.6% versus 91.6%, a positive predictive
value of 93% versus 93.1%, and a negative predictive
value of 91.6% versus 88%.
It is remarkable that all the patients with WD were
positive for at least ceruloplasmin or basal urinary cop-
per excretion.
In Table 4, the characteristics of CDG and NRH
patients (included in the control group) are summar-
ized. These patients intriguingly shared some biochem-
ical features with WD patients.
It is noteworthy that WD patients 23 and 24 (Table
2) were siblings who showed features very similar to
Fig. 2. ROC curves for different diagnostic tests for WD: (A) cerulo-
plasmin (area under the curve ¼ 0.94, 95% CI ¼ 0.88-0.99, P <
0.0001), (B) basal 24-hour urinary copper (area under the curve ¼
0.91, 95% CI ¼ 0.85-0.97, P < 0.0001), and (C) 24-hour urinary
copper after PCT (area under the curve ¼ 0.61, 95% CI ¼ 0.48-
0.74, P < 0.10). The broken lines represent the identity.
Table 3. Accuracy of Conventional Diagnostic Criteria for WD
at Different Thresholds
Test Cutoff Sensitivity (95% CI) Speciﬁcity (95% CI)
Ceruloplasmin
(mg/dL)
<10 65% (48.3%-79.4%) 96.5% (88.1%-99.6%)
<14 70% (53.5%-83.4%) 93.1% (83.3%-98.1%)
<18 80% (64.3%-90.9%) 91.4% (81%-97.1%)
<20 95% (83%-99.4%) 84.5% (72.6%-92.6%)
Basal 24-hour
urinary copper
(lg/24 hours)
>100 65.8% (48.6%-80.4%) 98.3% (90.8%-99.9%)
>40 78.9% (62.7%-90.4%) 87.9% (76.7%-95%)
24-hour urinary
copper after PCT
(lg/24 hours)
>1575 12% (2.5%-31.2%) 96.5% (88.1%-99.6%)
>500 64% (42.5%-82%) 51.7% (38.2%-65%)
>200 88% (68.8%-97.4%) 24.1% (13.9%-37.2%)
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those of CDG patients included in the control group,
but in both CDG was excluded on the basis of a nor-
mal transferrin isoelectric focusing proﬁle. Their serum
aminotransferase levels normalized after 20 or 4
months of penicillamine treatment.
Discussion
The features of our series are remarkably different
from those of other pediatric reports, which in most
cases have included WD children with either acute or
chronic symptomatic liver disease or liver failure.3,6-9,13
In fact, all the WD patients evaluated in the present
study were referred for raised aminotransferases and
could be considered asymptomatic or presymptomatic.
Therefore, this population represents a valuable speci-
men for assessing the appropriateness of the WD diag-
nostic criteria in children with mild liver disease. The
present study has highlighted different peculiarities of
these patients with respect to WD children reported
elsewhere.6-9,13
The measurement of ceruloplasmin serum levels is
also a ﬁrst-step test for the diagnosis of WD in chil-
dren with mild liver disease, as demonstrated by the
good sensitivity and acceptable speciﬁcity of this test at
the cutoff of 20 mg/dL in the studied population.
Obviously, low levels of ceruloplasmin are not always
indicative of a copper storage disorder because both
heterozygotes for WD and patients with other disor-
ders may share this feature.20-23 Furthermore, as
reported elsewhere, ceruloplasmin serum levels are also
inﬂuenced by the ATP7B genotype.24,25
As for basal daily urinary copper excretion, on the
basis of our results, the diagnosis of WD should be
considered when this test produces a value > 40 lg/
24 hours. This cutoff value has also been recently
stressed by AASLD guidelines,2 although its diagnostic
Fig. 3. WD diagnostic scores for WD patients and control subjects.
The broken line represents the score of certain diagnosis. The scores
were calculated under the assumption of basal urinary copper ULNs of
*40 and **100 lg/24 hours.
Table 4. Characteristics of Control Patients With CDG and NRH
Case Sex
Age at
Diagnosis
(Months)
KF
Rings
Serum
Copper
(lg/dL)
Ceruloplasmin
(mg/dL)
Basal
Urinary
Copper
(lg/24
Hours)
Urinary
Copper
After PCT
(lg/24
Hours)
Hepatic
Copper
(lg/g
of Dry
Weight) Laboratory Abnormalities
Liver
Biopsy
ATP7B
Genotype
WD
Score*
WD
Scorey
CDG Female 40 Neg 30 6 11 173 318 Total cholesterol, 240 mg/dL
(reference, <200 mg/dL);
creatine kinase, 200 U/L
(reference, 30-180 U/L)
S, F Neg 4 4
CDG Male 24 Neg 50 17 20 98 <50 INR, 1.54; PTT, 50 seconds;
A1AT serum level, 0.76 g/L
(reference, 0.9-2.0 g/L)
S, ACH Neg 1 1
CDG Male 18 Neg 77 19 7 190 <50 INR, 1.58; PTT, 44 seconds;
A1AT serum level, 0.8 g/L
(reference, 0.9-2.0 g/L);
haptoglobin, 0.3 g/L
(reference, 0.5-3.1 g/L)
S Neg 1 1
CDG Male 28 Neg 35 4 15 75 250 Total cholesterol, 220 mg/dL
(reference, <200 mg/dL);
creatine kinase, 210 U/L
(reference, 30-180)
S, F Neg 4 4
NRH Male 96 Neg 11 21 91 1479 ND Platelets, 70  109/L NRH Neg 1 2
NRH Male 108 Neg 105 31 30 1315 194 — NRH Neg 3 3
NRH Male 60 Neg 121 25 24 1666 ND — NRH ND 2 2
NRH Male 156 Neg 100 23 7 104 ND — NRH ND 0 0
NRH Male 192 Neg 90 22 20 1165 ND — NRH ND 2 2
The WD scores were calculated under the assumption of urinary copper ULNs of
**40 and
†100 lg/24 hours.
Abbreviations: A1AT, alpha-1-antitrypsin; ACH, active chronic hepatitis; F, ﬁbrosis; INR, international normalized ratio; Neg, negative; ND, not done; PTT, partial
thromboplastin time; S, steatosis.
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accuracy has not yet been deﬁned. There is only one
report describing a sensitivity of 68% at the cutoff
value of 40 lg/24 hours in an adult population.26
Among the adult series, the sensitivity of basal urinary
copper excretion at the cutoff value of 100 lg/24
hours is 59% to 88%.7,26,27 As for the pediatric series,
urinary copper levels have exceeded 100 lg/24 hours in
81% to 94% of cases.5,9,28 In symptomatic and asymp-
tomatic children, the sensitivity for basal cupriuria at the
cutoff value of 63.5 lg/24 hours is approximately 95%
and 70%, respectively.3,9 No data are available about the
speciﬁcity of this test because the cutoff value of 40 lg/
24 hours has never been evaluated; our results suggest
that this is the optimal threshold both as a single test
and in the context of the WD scoring system in chil-
dren with mild liver disease suspected of having WD.
The fact that urinary copper levels are lower in very
young children suggests an accumulation of the metal
over time. However, it is not possible to exclude the
idea that difﬁculties in daily urine collection in this age
group may have played a role, even if in our population
the parents underwent appropriate training and the daily
urine volume was consistent with the age and weight.
Current recommendations by the AASLD conclude
that PCTmay be performed in symptomatic children if a
diagnosis of WD is suspected but basal urinary copper
excretion is normal.2 Data about PCT sensitivity at the
cutoff value of 1575 lg/24 hours are very heterogeneous;
the sensitivity ranges from 69% to 88% in children with
active liver disease and from 46% to 56% in asymptom-
atic siblings.3,9 There is only one report showing a speci-
ﬁcity of 93% at the proposed cutoff of 1575 lg/24
hours.9 In this study, however, the group of asymptomatic
children was small (only 13 patients) and was not well
characterized with respect to liver enzymes. Our study
provides further and stronger evidence that PCT should
not be performed in children without symptomatic liver
disease regardless of the presence of neurological symp-
toms. In our series, only patients with more severe liver
damage according to a histological examination had a
positive PCT in both the WD and control groups, and
this suggests that copper excretion is inﬂuenced by the
severity of the liver injury. Moreover, the suggestion of
applying to children with basal urinary copper levels <
100 lg/24 hours a test with a cutoff value established
in a population of children with basal urinary copper
levels > 100 lg/24 hours9,13 is controversial.
The present study has shown that CDG can mimic
WD-related liver disease because patients with this dis-
order may present low serum levels of ceruloplasmin.
A correct differential diagnosis of WD versus CDG
may be challenging if we consider that the CDG
patients included in our control group presented with
an isolated liver disease in the absence of the typical
CDG phenotype characterized by severe neurological
involvement, dysmorphisms, and multiorgan impair-
ment. In these patients, further investigations for CDG
were triggered only by the presence of a mild coagulop-
athy not explained by the liver disease. It is noteworthy
that this novel CDG phenotype with prevalent liver
involvement has been recently recognized and character-
ized in asymptomatic children and young adults with
cryptogenic elevated aminotransferases and/or liver stea-
tosis with ﬁbrosis.23,29 The CDG patients, who were
included in the control group and were diagnosed as
being affected by a new phenotype called CDG-X,
shared with the WD patients low levels of ceruloplas-
min and high levels of liver copper, but in all of them,
WD was ruled out because of negative ATP7B gene
sequencing and spread haplotype analysis, low urinary
copper excretion (both at the baseline and after PCT),
and the absence of typical mitochondrial changes
according to an electron microscopy examination.
Tightly normal urinary copper excretion in these
patients could be taken into account as an affordable
tool for distinguishing them from patients with WD.
We can hypothesize that this phenotype results from a
disturbed redistribution of copper out of the liver via
ceruloplasmin because of the disturbed biosynthesis of
this glycoprotein in CDG, as observed in aceruloplas-
minemia. In aceruloplasminemic mice, the liver copper
content is augmented, but normal copper absorption,
transport, distribution, and excretion are observed.30
Furthermore, in our study, we found that patients
with NRH of the liver also shared some features with
WD patients. NRH is an uncommon benign condi-
tion characterized by diffuse transformation of the nor-
mal hepatic parenchyma into small, regenerative nod-
ules without ﬁbrosis; we found it to be associated with
high copper urine excretion after PCT, but the latter
ﬁnding is difﬁcult to interpret. Records of CDG and
NRH patients are displayed in Table 4.
Unlike urinary copper excretion, which was con-
ﬁrmed to be age-related as previously reported by our
group,24 the liver copper concentration did not seem
to be inﬂuenced in the present study by the age of the
patients, as documented by Ferenci et al.19 This dis-
crepancy remains unexplained. Studies of animal mod-
els, such as Rauch’s toxic milk mice, Jackson’s toxic
milk mice, and Long-Evans Cinnamon rats, are likely
to contribute to the clariﬁcation of the mechanism
affecting the accumulation of copper in the liver over
time. In these animals, with naturally occurring muta-
tions in their WD homologue Atp7b, the copper
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concentration in the liver increased with age in early
life and then remained fairly constant during the pro-
gression of liver disease.31-33 However, the results
obtained from a rodent model of WD are not neces-
sarily representative of the human mechanism of cop-
per accumulation.
In conclusion, establishing the diagnosis of WD is
problematic in children with mild liver disease. The
24-hour urinary copper excretion is highly informative
when 40 lg/24 hours is considered the ULN. The
WD scoring system proposed by Ferenci et al.11 may
be a reliable tool in this subset of patients if this limit
is used for evaluating the 24-hour urinary copper
excretion. PCT is of little value for diagnosis in these
patients. Other rare diseases may display low cerulo-
plasmin levels and even elevated hepatic parenchymal
copper levels; a genetic diagnosis remains critical for
such patients.
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